Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
India Business Strategies Innovation

Medtronic Invests $160M To Create Largest R&D Center Outside US

  • News

Executive Summary

Five-year investment will expand R&D center in Hyderabad and add 1,000 to workforce.

You may also be interested in...



Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Amwell Stock Rises 28% In Market Debut

Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.

Beyond Diabetes: Abbott Launches Glucose Sport Biosensor For Athletes To Track Blood Sugar

Analyst Larry Biegelsen expects Abbott’s CGM move into the consumer market could open a large new marketing opportunity.

Table

View full table

Topics

Related Companies

Tags:
India Business Strategies Innovation
UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By